Rumi Therapeutics signs option agreement for IND-ready RTX-7340 PDE2 inhibitor in Fragile X syndrome
Rumi Therapeutics secures an option to license RTX-7340 for Fragile X syndrome, with preclinical EEG findings supporting clinical development.
Pharma & Biotech
Pharma & Biotech
MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.